Cita APA (7a ed.)

Marques, P., Domingo, E., Rubio, A., Martinez-Hervás, S., Ascaso, J. F., Piqueras, L., . . . Sanz, M. (2022). Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players. Elsevier.

Cita Chicago Style (17a ed.)

Marques, Patrice, Elena Domingo, Arantxa Rubio, Sergio Martinez-Hervás, Juan F. Ascaso, Laura Piqueras, José T. Real, y Maria-Jesus Sanz. Beneficial Effects of PCSK9 Inhibition with Alirocumab in Familial Hypercholesterolemia Involve Modulation of New Immune Players. Elsevier, 2022.

Cita MLA (8a ed.)

Marques, Patrice, et al. Beneficial Effects of PCSK9 Inhibition with Alirocumab in Familial Hypercholesterolemia Involve Modulation of New Immune Players. Elsevier, 2022.